Lisdexamfetamine dimesylate capsules and chewable tablets are indicated for ADHD in patients aged 6 years and older, and for moderate to severe binge-eating disorder in adults.
Researchers compare viloxazine as a nonstimulant treatment option to atomoxetine for managing inattention, hyperactivity, and impulsivity in pediatric and adult patients with ADHD.
Investigators surveyed adolescents and young adults with self-reported ADHD to determine what proportion already engage in tolerance breaks from their medication, and how often.
Investigators assessed the impact of age at initiation of prescription stimulant medication and duration of stimulant therapy in adolescents with ADHD on rates of misuse of prescription stimulants, methamphetamine, or cocaine.
Researchers found that overall fracture incidence rate was 334 per 10,000 patient-years (PY) in the ADHD group versus 284 per 10,000 PY in the control group
Investigators searched publication database for studies concerning facial emotion recognition among individuals with attention-deficit/hyperactivity disorder.
Participants were evaluated by multiple sleep scale instruments and underwent polysomnography and multiple sleep latency tests following a 1-week actigraphy sleep assessment.
Researchers sought to characterize the prevalence of nootropic and psychostimulant use among individuals with ADHD and atopic dermatitis treated with and without dupilumab.
Investigators from the University of Oslo and the Norwegian Institute of Public Health sourced data for this prospective cohort study from the population-based Mother, Father and Child Cohort Study which pooled data from linked Norwegian registries.
The COVID-19 pandemic has had a significant impact on children and adults with ADHD. This case explores the effects long COVID has had on an adult patient with ADHD.
Investigators sought to evaluate the association between early childhood sleep and probable childhood ADHD diagnosis and if these prospective associations are mediated by childhood circulating inflammatory markers.
Meta-analysis shows no significant associations between ADHD medication use and cardiovascular disease risk for children, adolescents, or adults or for female patients.